Five-year Estimated Glomerular Filtration Rate in Patients With Hypoparathyroidism Treated With and Without rhPTH(1-84).
Adolescent
Adult
Aged
Aged, 80 and over
Calcitriol
/ administration & dosage
Calcium
/ administration & dosage
Chronic Disease
/ drug therapy
Female
Follow-Up Studies
Glomerular Filtration Rate
/ drug effects
Humans
Hydroxycholecalciferols
/ administration & dosage
Hypoparathyroidism
/ drug therapy
Male
Middle Aged
Parathyroid Hormone
/ administration & dosage
Randomized Controlled Trials as Topic
Recombinant Proteins
/ administration & dosage
Retrospective Studies
Treatment Outcome
Young Adult
chronic hypoparathyroidism
kidney function
recombinant human parathyroid hormone (1-84)
retrospective study
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
received:
06
11
2019
accepted:
30
07
2020
pubmed:
2
8
2020
medline:
20
2
2021
entrez:
2
8
2020
Statut:
ppublish
Résumé
Chronic hypoparathyroidism (HypoPT) is conventionally managed with oral calcium and active vitamin D. Recombinant human parathyroid hormone (1-84) (rhPTH[1-84]) is a therapy targeting the pathophysiology of HypoPT by replacing parathyroid hormone. To compare changes in the estimated glomerular filtration rate (eGFR) in patients with chronic HypoPT receiving or not receiving rhPTH(1-84) during a 5-year period. A retrospective analysis of patients with chronic HypoPT treated with or without rhPTH(1-84). Sixty-nine patients with chronic HypoPT from 4 open-label, long-term trials (NCT00732615, NCT01268098, NCT01297309, and NCT02910466) composed the rhPTH(1-84) cohort and 53 patients with chronic HypoPT not receiving rhPTH(1-84) from the Geisinger Healthcare Database (01/2004-06/2016) composed the historical control cohort. The rhPTH(1-84) cohort (N = 69) received rhPTH(1-84) therapy; the historical control cohort (N = 53) did not receive rhPTH(1-84). Changes in eGFR from baseline during a 5-year follow-up were examined in multivariate regression analyses. At baseline, demographic characteristics and eGFR were similar between cohorts, though the proportions with diabetes and cardiac disorders were lower in the rhPTH(1-84) cohort. At the end of follow-up, mean eGFR increased by 2.8 mL/min/1.73 m2 in the rhPTH(1-84) cohort, while mean eGFR fell by 8.0 mL/min/1.73 m2 in the control cohort. In the adjusted model, the difference in the annual eGFR change between the rhPTH(1-84) cohort and the control cohort was 1.7 mL/min/1.73 m2 per year (P = 0.009). Estimated glomerular filtration rate was preserved for over 5 years among patients with chronic HypoPT receiving rhPTH(1-84) treatment, contrasting with an eGFR decline among those not receiving rhPTH(1-84).
Identifiants
pubmed: 32738041
pii: 5879689
doi: 10.1210/clinem/dgaa490
pmc: PMC7470469
pii:
doi:
Substances chimiques
Hydroxycholecalciferols
0
PTH protein, human
0
Parathyroid Hormone
0
Recombinant Proteins
0
Calcitriol
FXC9231JVH
Calcium
SY7Q814VUP
alfacalcidol
URQ2517572
Banques de données
ClinicalTrials.gov
['NCT00732615', 'NCT01268098', 'NCT01297309', 'NCT02910466']
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Endocrine Society 2020.
Références
J Bone Miner Res. 2018 May;33(5):822-831
pubmed: 29281760
J Bone Miner Res. 2018 Mar;33(3):478-485
pubmed: 29087618
J Bone Miner Res. 2015 Sep;30(9):1738-44
pubmed: 25753591
N Engl J Med. 1978 Jun 1;298(22):1241-3
pubmed: 651964
J Bone Miner Res. 2013 Nov;28(11):2277-85
pubmed: 23661265
J Bone Miner Res. 2014 Nov;29(11):2504-10
pubmed: 24806578
Kidney Int. 1987 Nov;32(5):760-71
pubmed: 2828751
Lancet Diabetes Endocrinol. 2013 Dec;1(4):275-83
pubmed: 24622413
J Bone Miner Res. 2011 Oct;26(10):2317-37
pubmed: 21812031
Front Endocrinol (Lausanne). 2017 Jan 16;7:172
pubmed: 28138323
J Clin Endocrinol Metab. 2013 Jan;98(1):137-44
pubmed: 23162103
J Clin Endocrinol Metab. 2008 Sep;93(9):3307-9
pubmed: 18772463
BMC Surg. 2016 Aug 03;16(1):51
pubmed: 27488573
Eur J Endocrinol. 2015 Aug;173(2):G1-20
pubmed: 26160136
J Clin Endocrinol Metab. 2016 Aug;101(8):3045-53
pubmed: 27186861
J Clin Endocrinol Metab. 2012 Dec;97(12):4507-14
pubmed: 23043192
Cancer. 2000 Jul 1;89(1):202-17
pubmed: 10897019
J Clin Invest. 1992 Sep;90(3):749-58
pubmed: 1522230
Pharmacotherapy. 2008 Sep;28(9):1125-32
pubmed: 18752383
Br Med J. 1977 Jan 8;1(6053):78-81
pubmed: 832019
J Bone Miner Res. 2013 Dec;28(12):2570-6
pubmed: 23737456
N Engl J Med. 2000 Dec 21;343(25):1863-75
pubmed: 11117980
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Endocrine. 2017 Jan;55(1):273-282
pubmed: 27734257
J Clin Endocrinol Metab. 2016 Jul;101(7):2742-50
pubmed: 27144931